# BEHOLD-Endometrial01 (NCT07286331)

> A Study to Investigate Mocertatug Rezetecan Compared With Chemotherapy in Participants With Endometrial Cancer After Platinum-based Chemotherapy and Immunotherapy (BEHOLD-Endometrial01)

No report yet. It can be ordered.

- Drugs tested: mocertatug rezetecan
- Indication: endometrial cancer after platinum-based chemotherapy and immunotherapy

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT07286331
- Phase: PHASE3
- Status: RECRUITING
- Sponsor: GlaxoSmithKline
- Conditions: Neoplasms, Endometrial
- Interventions: Mocertatug rezetecan; Paclitaxel; Doxorubicin
- Enrollment: 600
- Primary outcome: Objective response rate (ORR) by BICR
- Primary outcome: Progression Free Survival (PFS) by BICR

## Indexed commentary on BEHOLD-Endometrial01 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 2
- YouTube: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=behold-endometrial01-nct07286331